Isatuximab in Multiple Myeloma

The addition of isatuximab to pomalidomide and low-dose dexamethasone significantly improved PFS and overall response rate among patients with relapsed or refractory multiple myeloma according to randomized phase 3 study results presented at ASCO Annual M [...]